Know Cancer

forgot password

A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission

Phase 2
60 Years
Not Enrolling
Acute Myeloid Leukemia

Thank you

Trial Information

A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission

To determine if you are eligible to participate in this study you will be asked to undergo
some screening tests or procedures. Many of these tests and procedures are likely to be part
of regular cancer care and may be done even if it turns out you do not take part in the
research study. If you have had some of these tests or procedures recently, they may or may
not have to be repeated. These procedures include a medical history, performance status,
medical record review, routine blood tests, electrocardiogram, echocardiogram and research
blood samples. If these tests show that you are eligible to participate in the research
study, you will begin the study treatment. If you do not meet the eligibility criteria, you
will not be able to participate in this research study.

You will begin the study with up to two cycles of chemotherapy that is an accepted approach
treatment of your type of leukemia. This is called consolidation chemotherapy. If you
experience severe side effects, you may only be given one cycle. You will begin to take
sulindac after you complete consolidation therapy. The consolidation therapy that is
commonly used for your type of cancer is a chemotherapy drug called cytarabine. Each cycle
of consolidation chemotherapy will be 28 days, or four weeks. You will receive cytarabine
via IV infusion on Days 1-5 of each cycle, over a period of 3 hours. You will be admitted to
MGH for approximately a week during each cycle of consolidation chemotherapy with

Before starting sulindac, the same tests and procedures done at the screening visit listed
above will be repeated. This visit is "Day 0", meaning it takes place prior to study
treatment with sulindac. In addition, you will also have a sample of your bone marrow taken
for research purposes. This sample is related to the study and will help us understand
better the activity of the study drug, sulindac, on leukemia cells and the effect of the
body on the sulindac.

You will take sulindac twice a day. Sulindac comes in the form of tablets and can be taken
at home by mouth. Your first day of taking sulindac will be called day 1. The following
tests and procedures will be one in the outpatient clinic on Day 1 of the study: Blood
samples will be taken at 3 points on day 1. These will occur before the first dose of
sulindac, 1 hour after the first dose of sulindac, and 4 hours after the first dose of
sulindac. Approximately 3 teaspoons of blood will be drawn each time. These samples are
related to the study and will help us understand better the activity of the study drug,
sulindac, on leukemia cells and the effect of the body on sulindac.

You will come into the clinic for dosing on day 2 (Visit 3) of the study. Approximately 3
teaspoons of blood will be drawn before dosing. 3 teaspoons of blood will also be drawn
prior to dosing on days 8, 15 and 28 of study treatment with sulindac. These samples will be
stored for as long as research is ongoing with currently no end date. You will continue
sulindac twice daily for the duration of the study, which will be 12 months.

You will be monitored for bleeding, since COX inhibitors can also decrease platelet function
and affect clotting abilities, and for gastritis or ulcer disease, as COX inhibitors can
damage the lining of the stomach. These occur in the minority of participants, but you will
be monitored closely on this study for these unexpected effects.

If you develop toxicities on therapy, your dose of sulindac may be reduced or if your
symptoms are severe enough, you may be taken off sulindac. If for whatever reason you are
unable to participate in the study or adhere to the schedules and study treatments, you will
be taken off the study treatment and discontinued from the study. You may choose to stop
treatment and come off the study at any time.

We would like to keep track of your medical condition and overall health following the 12
months of study treatment on study with sulindac. This will not involve any communication,
but only occasional review of your medical record in regards to medical condition and
overall health.

Inclusion Criteria:

- Pathologically confirmed newly diagnosed acute myelogenous leukemia in complete
remission following induction chemotherapy

Exclusion Criteria:

- Plan for consolidative stem cell transplant in CR1 at the time of enrollment

- Previous history of coronary artery disease or heart failure

- Previous history of major allergic reaction to aspirin or other non-steroidal
anti-inflammatory drugs

- Previous history of gastric or duodenal ulceration

- Diagnosis of acute promyelocytic leukemia

- Diagnosis of acute bilineal/biphenotypic leukemia

- History of a different malignancy unless disease free for at least 5 years or
diagnosed and treated for cervical cancer in situ, basal or squamous cell carcinoma
of the skin

- Uncontrolled intercurrent illness that would limit compliance with study requirements

- Disseminated intravascular coagulation

- HIV positive on combination anti-retroviral therapy

- Known active hepatitis B or C

- History of coronary artery disease

- Current or history of congestive heart failure

- History of ventricular arrhythmia

- Patients with mental deficits or psychiatric conditions that preclude them form
giving informed consent and following protocol

- Pregnant

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy of sulindac in maintaining complete remission

Outcome Description:

To define the efficacy of the COX inhibitor sulindac in maintaining complete remission in older patients with AML who achieve remission after induction chemotherapy

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Amir Fathi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital


United States: Food and Drug Administration

Study ID:




Start Date:

January 2014

Completion Date:

Related Keywords:

  • Acute Myeloid Leukemia
  • Newly diagnosed
  • Complete Remission
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid



Massachusetts General HospitalBoston, Massachusetts  02114-2617